Date: 2011-12-08
Type of information: R&D agreement
Compound: novel genetically customized cell lines for drug discovery studies
Company: Cellectis (France) Syngene International (India)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Cellectis Bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis and Syngene International Ltd, an internationally reputed contract research and manufacturing services (CRAMS) organization and subsidiary of BIOCON Ltd, India’s largest biotechnology company by revenue, have entered into an agreement to develop novel genetically customized cell lines. This partnership between Cellectis Bioresearch and Syngene will leverage Cellectis’ patented technology in genome customization with Syngene’s strong biology platform and capabilities to develop novel recombinant and knock-out cell lines for use in oncology- and ADME-Tox-based drug discovery studies.
Financial terms: Financial details were not disclosed.
Latest news:
